Lipigon Pharmaceuticals
0.35 SEK +9.37%1 investor is following this company
Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are mainly treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and associated ancillary services are also offered. Lipigon Pharmaceuticals operates worldwide, with the largest presence in the Nordic market.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LPGO
Daily low / high price
0.31 / 0.37
SEK
Market cap
51.92M SEK
Turnover
253.49K SEK
Volume
759K
Financial calendar
Interim report
2024-08-27
Interim report
2024-11-21
Annual report
2025-02-19
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Nordnet Pensionsförsäkring AB | 9.6 % | 9.6 % |
Försäkringsaktiebolaget Avanza Pension | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study
Lipigon erhåller milstolpsbetalning på 1 MUSD från Leaderna för godkännande av fas I-bryggstudie
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools